Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings from a win ratio analysis ...

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD) ...

In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for ...

Real-world data from Australian patients show that upadacitinib demonstrates strong efficacy in treating atopic dermatitis, ...

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Sanofi has unveiled plans to invest “at least” $20bn into the US by 2030, with the commitment including a significant ...